<DOC>
	<DOC>NCT02586350</DOC>
	<brief_summary>To compare the effects and safety of Anlotinib with placebo in patients with Medullary Thyroid Carcinoma.</brief_summary>
	<brief_title>Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Neuroendocrine</mesh_term>
	<criteria>1. Signed and dated informed consent 2. Histological documentation of medullary thyroid carcinoma(MTC),Unable to surgery(Stage IV) or metastasis ,With measurable disease (using RECIST1.1) 3. ECOG PS:01,Life expectancy of more than 6 months 4. main organs function is normal 1. Prior treatment with Anlotinib or VEGFRtargeted therapies(such as Vandetanib,Cabozantinib,Lenvatinib,Sunitinib,Sorafenib etc.) 2. Subjects received radiotherapy external exposure within 3 months prior to the first dose of study drug or plan to be received any anticancer treatment during study 3. Patients suffering from other malignancies currently or within 5 years, except for cured cervical carcinoma in situ, nonmelanoma skin cancers and superficial bladder cancer [ Ta (noninvasive carcinoma), Tis (carcinoma in situ) and T1 (carcinoma invasion into lamina propria) ] 4. CTCAE(4.0) Grade 1 or higher nonremission toxicity induced by any other previous treatments，excluding alopecia and Grade 2 or lower neurotoxicity induced by oxaliplatin 5. Patients with factors that could affect oral medication (such as dysphagia etc.) 6. Patients with pleural effusion or ascites, causing respiratory syndrome (CTCAE Grade 2 or higher dyspnea [Grade 2 dyspnea refers to Shortness of breath with a small amount of activities, affecting Instrumental activities of daily life]) 7. Patients underwent major surgical treatment，open biopsy or significant traumatic injury within 28 days prior to assignment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>